Literature DB >> 832438

"Alice in Wonderland" syndrome as a presenting symptom of infectious mononucleosis in children: a description of three affected young people.

S M Copperman.   

Abstract

Three cases of "Alice in Wonderland" syndrome (metamorphopsia) are presented and described as a presenting symptom of infectious mononucleosis in a preadolescent male and in two late teenage females. In each instance, the classical infectious mononucleosis symptoms and diagnosis followed the onset of visual aberration. Thorough physical and blood examination of patients who present with such a syndrome must be undertaken before these symptoms are ascribed to psychiatric abnormalities. It is emphasized that infectious mononucleosis is a diffuse disorder, often associated with encephalopathies, which may include visual imbalance symptoms.

Entities:  

Mesh:

Year:  1977        PMID: 832438     DOI: 10.1177/000992287701600205

Source DB:  PubMed          Journal:  Clin Pediatr (Phila)        ISSN: 0009-9228            Impact factor:   1.168


  5 in total

1.  Vaccine efficacy and control measures in pertussis.

Authors:  S R Palmer
Journal:  Arch Dis Child       Date:  1991-07       Impact factor: 3.791

2.  "Alice in Wonderland" syndrome and infectious mononucleosis in children.

Authors:  E Lahat; G Eshel; A Arlazoroff
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-12       Impact factor: 10.154

3.  Facial dysmorphopsia: a notable variant of the "thin man" phenomenon?

Authors:  Martin Ganssauge; Eleni Papageorgiou; Ulrich Schiefer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-03-03       Impact factor: 3.117

Review 4.  [Migraine variants and unusual types of migraine in childhood].

Authors:  C Gaul; T Kraya; D Holle; I Benkel-Herrenbrück; U Schara; F Ebinger
Journal:  Schmerz       Date:  2011-04       Impact factor: 1.107

5.  Alice in Wonderland syndrome as an initial manifestation of Epstein-Barr virus infection.

Authors:  M Cinbis; S Aysun
Journal:  Br J Ophthalmol       Date:  1992-05       Impact factor: 4.638

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.